Solid Biosciences Inc
SLDB
View Detailed Chart
5.900USD
-0.080-1.34%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
459.51MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.34%
5 Days
+3.33%
1 Month
+25.53%
6 Months
+23.17%
Year to Date
+47.50%
1 Year
+41.83%
View Detailed Chart
TradingKey Stock Score of Solid Biosciences Inc
Currency: USD Updated: 2025-12-22Key Insights
Solid Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 37/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.23.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Solid Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
14
analysts
Buy
Current Rating
15.231
Target Price
+166.74%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Solid Biosciences Inc Highlights
StrengthsRisks
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -2.42, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 82.26M shares, decreasing 7.08% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 6.48K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.46.
Solid Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Solid Biosciences Inc Info
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Ticker SymbolSLDB
CompanySolid Biosciences Inc
CEOCumbo (Alexander)
Websitehttps://www.solidbio.com/
FAQs
What is the current price of Solid Biosciences Inc (SLDB)?
The current price of Solid Biosciences Inc (SLDB) is 5.900.
What is the symbol of Solid Biosciences Inc?
The ticker symbol of Solid Biosciences Inc is SLDB.
What is the 52-week high of Solid Biosciences Inc?
The 52-week high of Solid Biosciences Inc is 7.370.
What is the 52-week low of Solid Biosciences Inc?
The 52-week low of Solid Biosciences Inc is 2.410.
What is the market capitalization of Solid Biosciences Inc?
The market capitalization of Solid Biosciences Inc is 459.51M.
What is the net income of Solid Biosciences Inc?
The net income of Solid Biosciences Inc is -124.70M.
Is Solid Biosciences Inc (SLDB) currently rated as Buy, Hold, or Sell?
According to analysts, Solid Biosciences Inc (SLDB) has an overall rating of Buy, with a price target of 15.231.
What is the Earnings Per Share (EPS TTM) of Solid Biosciences Inc (SLDB)?
The Earnings Per Share (EPS TTM) of Solid Biosciences Inc (SLDB) is -2.476.
Related Instruments
-0.47%
-0.75%
+0.38%
+0.64%
+1.64%
+0.32%
+0.03%
+7.32%
+0.83%
-1.31%
+0.60%
-0.24%
-0.71%
+0.88%
+0.50%
+1.55%
+0.75%
0.00%
-0.19%
-2.21%
